Merck Global Health Innovation Fund

Verge Genomics Secures $98 Million in New Financing

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, Health, Pharmaceutical, Other Technology, Technology, Tao, Lilly, BlackRock, Series, Company, Genomics, ALS, Eli Lilly and Company, Venture round, LLC, Health, Drug discovery, CEO, Machine learning, Vulcan Inc., Artificial intelligence, Patient, Drug development, Neuroscience, Section 32, Verge, Efficiency, Investment, Program, GHI, Digital health, Amyotrophic lateral sclerosis, Partnership, Digital, Technology, Pharmaceutical industry, Medical device, Merck, Verge Genomics, Merck Global Health Innovation Fund, VERGE GENOMICS, MERCK GLOBAL HEALTH INNOVATION FUND

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing.

Key Points: 
  • Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing.
  • Verge has built an end-to-end, AI-driven drug discovery platform that includes one of the fields largest proprietary genomic datasets from human brain tissue.
  • Verge has built an end-to-end drug discovery and development platform, featuring one of the fields largest and most comprehensive proprietary patient genomics datasets in neuroscience.
  • www.merckghifund.com
    Shumaker, Loop & Kendrick LLP and Green Shoots Consulting, LLC acted as advisors to Merck GHI in connection with the Verge Genomics transaction.

Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

Retrieved on: 
Wednesday, October 20, 2021
Data Management, Other Health, Technology, Pharmaceutical, General Health, Professional Services, Venture Capital, Clinical Trials, Other Technology, Biotechnology, Science, Software, Other Science, Internet, Research, Health, Cloud, Clinical trial, CG, NASDAQ, Guggenheim, Martha Plimpton, Digital, LSAC, View, Data management, COVID-19, EFront Alternative Investment Solutions, GHI, Drug development, Health, Oliver Cromwell, Digital health, Research, Vaccine, CEO, Solution, Patient, NDAS, Industry, Â, HarbourVest Global Private Equity, Partnership, Investment, Sullivan & Cromwell, Company, Pharmaceutical industry, Saama Technologies, Inc., Carlyle, Merck Global Health Innovation Fund, SAAMA TECHNOLOGIES, INC., CARLYLE, MERCK GLOBAL HEALTH INNOVATION FUND

Saama Technologies, Inc. (Saama) today announced funds led by global investment firm Carlyle (NASDAQ: CG) have made a strategic growth investment and will acquire a majority stake in the Company.

Key Points: 
  • Saama Technologies, Inc. (Saama) today announced funds led by global investment firm Carlyle (NASDAQ: CG) have made a strategic growth investment and will acquire a majority stake in the Company.
  • The partnership will allow Saama to accelerate its strategic initiatives, including expanding its go-to-market capabilities and further investing in AI research and development.
  • Saamas intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
  • This investment by Carlyle and leading healthcare-focused venture funds reflects the value they see in Saamas leadership of this new era and the promise offered by our state-of-the-art solutions.

Octave Bioscience Announces Strategic Investment from the Merck Global Health Innovation Fund to Transform Disease Measurement and Care for Patients with Neurodegenerative Diseases

Retrieved on: 
Tuesday, October 12, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Population health, Brain, Inflammation, Digital health, Health, Biology, Digital, Neurology, Decision-making, MS, Physician, Spine, List of life sciences, GHI, Industry, HIV disease progression rates, Neurodegeneration, Population, Investment, MRI, Multiple sclerosis, Founder, CNS, Patient, View, Pharmaceutical industry, Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, the Octave Bioscience Comprehensive Care Platform, Octave Bioscience, Merck Global Health Innovation Fund, THE OCTAVE BIOSCIENCE COMPREHENSIVE CARE PLATFORM, OCTAVE BIOSCIENCE, MERCK GLOBAL HEALTH INNOVATION FUND

Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF ) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases.

Key Points: 
  • Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF ) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases.
  • Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS.
  • Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases.
  • Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy.

 Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship

Retrieved on: 
Tuesday, May 19, 2020
Insurance, Infectious diseases, Hospitals, Professional services, Practice Management, Biotechnology, Health, Pharmaceutical, General Health, Articles, Health, Infectious diseases, Epidemiology, Medical specialties, Infectious disease, Antimicrobial stewardship, Infection, Telehealth, UPMC, Merck Global Health Innovation Fund, Merck

Infectious Disease Connect has established a telemedicine solution for infectious disease care enabling doctors to access the expertise of an infectious disease specialist to facilitate timely diagnosis and treatment of patients under their care.

Key Points: 
  • Infectious Disease Connect has established a telemedicine solution for infectious disease care enabling doctors to access the expertise of an infectious disease specialist to facilitate timely diagnosis and treatment of patients under their care.
  • ILM uses machine learning to evaluate a patients demographic factors, medication history, past hospitalizations and other data to generate individualized treatment recommendations.
  • The company can provide hospitals with infectious disease expertise and tools to help meet new federal regulations requiring evidence-based antimicrobial stewardship programs that produce measurable results.
  • Infectious Disease Connect, headquartered in Pittsburgh, will continue to serve ILMs hospital customers and integrate most of its employees.